The kidney and bone metabolism: Nephrologists' point of view.
The kidney plays an important role in the regulatory system for bone and mineral metabolism. In chronic kidney disease (CKD), various abnormalities, recently named CKD-mineral and bone disorder (CKD-MBD), may develop in this system. The optimal management of CKD-MBD should be achieved without increasing the risk of metastatic calcification, including that of blood vessels. Thus, it is quite important to identify severe cases of hyperparathyroidism refractory to medical therapy. The size of the parathyroid glands, serum levels of fibroblast growth factor (FGF)23, and, possibly, the overproduction of a novel form of parathyroid hormone (PTH), serve as useful markers for this purpose. Adynamic bone disease with low buffering capacity for calcium is another major cause of hypercalcemia in dialysis patients. Our recent studies suggest that indoxyl sulfate accumulated in uremic serum is responsible for the suppression of osteoblastic function. In order to maintain the bone quality in patients with CKD, bone changes due to aging, menopause, and malnutrition need to be considered by nephrolgists and non-nephrologists in collaboration.
Fukagawa
Masafumi
M
Division of Nephrology and Dialysis Center, Kobe University School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. fukagawa@med.kobe-u.ac.jp
Hamada
Yasuhiro
Y
Nakanishi
Shohei
S
Tanaka
Motoko
M
D000818:Animals; D001842:Bone and Bones / Q000378:metabolism*; D000089703:Fibroblast Growth Factor-23; D006801:Humans; D007668:Kidney / Q000378:metabolism*; D007674:Kidney Diseases / Q000276:immunology / Q000378:metabolism* / Q000628:therapy; D008903:Minerals / Q000378:metabolism; D009398:Nephrology; D010281:Parathyroid Hormone / Q000378:metabolism
C000717427:FGF23 protein, human; D008903:Minerals; D010281:Parathyroid Hormone; D000089703:Fibroblast Growth Factor-23